We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical

229 hedge funds and large institutions have $2.76B invested in Ultragenyx Pharmaceutical in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 89 increasing their positions, 77 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

16% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 77

11% more capital inflows, than outflows

Capital inflows: $255M | Capital outflows: $229M

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

0.78% more ownership

Funds ownership: 97.08% → 97.86% (+0.78%)

0% more funds holding

Funds holding: 229 → 229 (0)

12% less call options, than puts

Call options by funds: $9.19M | Put options by funds: $10.4M

Holders
229
Holders Change
–
Holders Change %
0%
% of All Funds
3.64%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.08%
New
28
Increased
89
Reduced
77
Closed
26
Calls
$9.19​M
Puts
$10.4​M
Net Calls
-⁠$1.23​M
Net Calls Change
-⁠$3.51​M

RARE Hedge Fund Activity: Q1 2023 in Review

229 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2023, worth a combined $2.76B — down 13% from $3.15B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new RARE positions and 26 closed out — a net gain of 2 holders — while 89 added to existing stakes and 77 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $28.3M. The largest seller was Avidity Partners Management, cutting an estimated $37M.

  • 229 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $2.76B of Ultragenyx Pharmaceutical stock for Q1 2023, down 13% quarter-over-quarter.
  • 28 funds opened new Ultragenyx Pharmaceutical positions in Q1 2023 and 26 closed out, a net change of +2 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q1 2023 was Point72 Asset Management, an estimated $28.3M added.
  • The largest Ultragenyx Pharmaceutical seller in Q1 2023 was Avidity Partners Management, an estimated $37M sold.

Based on aggregated 13F filings for Q1 2023.